The World Health Organization and Costa Rica will launch a technology pooling initiative to help fight the COVID-19 pandemic.
Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the European Union Intellectual Property Office.
India has imposed export restrictions on drugs and active pharmaceutical ingredients (APIs), including paracetamol, amid fears over COVID-19-related shortages.
Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.
British drugmaker GSK and Chinese biotech Clover Biopharmaceuticals have partnered to develop a protein-based coronavirus vaccine candidate.
Indian drugmaker Zydus Cadila has launched a fast track programme to develop a vaccine for the novel coronavirus COVID-19, which has so far claimed more than 1,600 lives worldwide.
A state-run institution in China has applied for a patent on the use of an experimental Gilead Sciences drug, which scientists believe may be able to fight the coronavirus outbreak that has killed hundreds.
Bayer has dropped trade secrets claims against a former employee and rival company, which it had accused of stealing confidential information related to organic fungicides.
Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.
Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.